<DOC>
	<DOCNO>NCT00987870</DOCNO>
	<brief_summary>This study determine efficacy topical BFH772 psoriasis patient safety multiple dosing .</brief_summary>
	<brief_title>Safety Efficacy BFH772 Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Stable mild moderate plaque psoriasis ( BSA involvement &lt; 10 % PASI &lt; 10 Category `` mild moderate '' PGA accord EMEA ( CHMP 2004 ) ( Guideline clinical investigation medicinal product indicate treatment psoriasis ) , without arthritis Diagnosed history psoriasis least 6 month prior screen Nonplaque form psoriasis Druginduced psoriasis Current use beta blocker Congestive heart failure ( NYHA &gt; III ) , QT interval &gt; 450msec poorly control diabetes mellitus Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Stable plaque Psoriasis</keyword>
	<keyword>inflammatory skin</keyword>
	<keyword>without arthritis</keyword>
</DOC>